{"gene":"BACE2","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2000,"finding":"BACE2 cleaves APP at the beta-secretase site (Asp1) and more efficiently at a site within the Aβ domain (near Phe19-Phe20); the Flemish missense mutation of APP markedly increases Aβ production by BACE2 but not BACE1; mutation of a conserved active-site Asp inhibits beta-site cleavage but not cleavage within Aβ by both enzymes.","method":"Cell-based cleavage assays, active-site mutagenesis, APP mutant analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro/cell-based cleavage assays combined with active-site mutagenesis in a focused study","pmids":["10931940"],"is_preprint":false},{"year":2000,"finding":"BACE2 is a membrane-anchored aspartic protease with a predicted transmembrane region; in vitro translation and cell transfection showed it encodes a glycosylated protein that localizes mainly intracellularly but also to some extent at the plasma membrane.","method":"In vitro translation, cell transfection, glycosylation analysis","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — cell transfection and in vitro translation, single lab, two methods","pmids":["10683441"],"is_preprint":false},{"year":2000,"finding":"ASP1 (BACE2) expressed as an Fc fusion protein exhibits beta-secretase activity, cleaving both wild-type and Swedish-variant APP peptides at the beta-secretase site; overexpression of ASP1 in APP-expressing cells increases beta-secretase-derived soluble APP and the corresponding C-terminal fragment, but paradoxically decreases soluble Aβ secretion; ASP1 co-localizes with APP in Golgi/ER compartments.","method":"Cell-based overexpression, N-terminal sequencing of fusion protein, immunocytochemistry","journal":"Molecular and cellular neurosciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based functional assay with protein-level readout and colocalization, single lab","pmids":["11083922"],"is_preprint":false},{"year":2001,"finding":"BACE2 prodomain processing is autocatalytic: cleavage occurs between Leu62 and Ala63; BACE2 cleaved a maltose-binding protein–prodomain fusion and a synthetic peptide at this site; mutation of the catalytic Asp (D110N) abolished processing; prodomain removal occurs intramolecularly within the ER/early Golgi, and mature BACE2 is expressed on the cell surface.","method":"Mutagenesis (D110N active-site mutant), fusion protein cleavage assay, synthetic peptide cleavage, cell fractionation/surface expression analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — active-site mutagenesis combined with in vitro peptide cleavage assay and cell biological localization, single lab with multiple orthogonal methods","pmids":["11316808"],"is_preprint":false},{"year":2001,"finding":"In cells, BACE2 functions primarily as an alternative alpha-secretase, cleaving APP near the alpha-secretase site (mainly Phe19-Phe20 and Phe20-Ala21) with limited effect at the beta-site; purified BACE2 can be autoactivated in vitro; BACE2 localizes to ER, Golgi, TGN, endosomes, and plasma membrane, with localization dependent on its transmembrane domain; BACE2 chimeras that increase TGN localization do not alter APP processing patterns.","method":"Purified protein autoactivation, cell-based APP processing assay, subcellular localization by immunofluorescence, chimeric protein analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — purified protein in vitro assay, cell-based processing, and localization studies with chimeras, single lab with multiple orthogonal methods","pmids":["11423558"],"is_preprint":false},{"year":2002,"finding":"BACE2 cleaves APP in cells between Phe19 and Phe20 within the Aβ domain (not at the beta-secretase site), resulting in increased APPsα and p3-like products and reduced Aβ production; this cleavage occurs in the Golgi and later secretory compartments; radiosequencing of the membrane-bound C-terminal cleavage product confirmed the exact cleavage site.","method":"Radiosequencing of C-terminal cleavage products, cell-based APP processing, compartment-specific analysis","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — radiosequencing (direct biochemical identification of cleavage site) combined with cell-based processing analysis, single lab","pmids":["12065613"],"is_preprint":false},{"year":2003,"finding":"Stably transfected HEK293 cells overexpressing BACE2 produce the C-terminal fragment C79 (corresponding to cleavage between Phe19-Phe20), less genuine Aβ1-40/42, and higher sAPPβ and N-terminal-truncated Aβ species; BACE2 activity is enhanced by the Swedish APP mutation and is maximal at pH 4.5.","method":"Stable cell transfection, characterization of APP-derived catabolites, fluorimetric assay at varying pH","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — stable cell lines with biochemical characterization of products, pH-activity profiling, single lab","pmids":["12736275"],"is_preprint":false},{"year":2005,"finding":"Crystal structure of mature BACE2 in complex with a hydroxyethylamine transition-state inhibitor determined at 3.1 Å; structure confirms BACE2 follows the general fold of A1 aspartic proteases but its C-terminal domain is larger than other family members; differences in S3, S2, S1' and S2' active-site substrate pockets compared to BACE1 were identified; mature BACE2 was produced by autocatalytic activation of pro-BACE2 refolded from E. coli inclusion bodies.","method":"X-ray crystallography, recombinant protein expression and refolding, autocatalytic activation","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure determination with functional validation (autocatalytic activation), provides structural basis for active-site differences","pmids":["16305800"],"is_preprint":false},{"year":2006,"finding":"BACE2 cleaves APP at a novel theta (θ) site downstream of the alpha-site, abolishing Aβ production; lentiviral overexpression of BACE2 markedly reduces Aβ production in primary neurons from Swedish-mutant APP transgenic mice; BACE1, not BACE2, is responsible for the major beta-secretase activity in Down syndrome.","method":"Lentiviral overexpression, primary neuronal culture, Aβ ELISA, APP cleavage site mapping","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — lentiviral overexpression with Aβ quantification in primary neurons, single lab","pmids":["16816112"],"is_preprint":false},{"year":2005,"finding":"BACE2 overexpression significantly increases sAPP levels (non-amyloidogenic) in conditioned media and markedly reduces Aβ production; knockdown of BACE2 results in increased APP C83; BACE2 processes APP within the Aβ domain at a site downstream of the alpha-secretase cleavage site, not at the beta-site; BACE2 and BACE1 have distinct transcriptional regulation (TATA-less promoter, Sp1 can regulate both but promoters share little similarity).","method":"Overexpression/knockdown in cells, sAPP and Aβ quantification, promoter characterization, transcription factor analysis","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based gain- and loss-of-function with biochemical readouts, single lab","pmids":["15857888"],"is_preprint":false},{"year":2011,"finding":"Bace2 is the sheddase of the proproliferative plasma membrane protein Tmem27 in pancreatic β-cells; identified through siRNA screen; mice with functionally inactive Bace2 and insulin-resistant mice treated with a BACE2 inhibitor both display augmented β-cell mass and improved glucose homeostasis due to increased insulin levels.","method":"siRNA screen, genetic knockout mice, pharmacological inhibition, glucose homeostasis measurements, β-cell mass quantification","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — siRNA screen identification plus genetic KO mice and pharmacological inhibition with defined physiological readouts, replicated across multiple experimental systems","pmids":["21907142"],"is_preprint":false},{"year":2012,"finding":"Tmem27 dimerization (mediated by intracellular cysteine) prevents Bace2 cleavage; extracellular asparagine glycosylation is essential for Tmem27 trafficking to the plasma membrane and its processing by Bace2; the amount of Tmem27 at the plasma membrane is proportional to total cell levels upon glucose stimulation and Bace2 inhibition; the double phenylalanine motif in the Tmem27 cleavage site acts as an intramolecular Bace2 inhibitor.","method":"Tmem27 mutational analysis, co-immunoprecipitation, glycosylation mutants, pharmacological inhibition, cell surface biotinylation","journal":"Biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — mutational analysis combined with multiple biochemical approaches defining substrate structural requirements for cleavage, single lab","pmids":["22628310"],"is_preprint":false},{"year":2012,"finding":"BACE2 is a potent Aβ-degrading protease in vitro, cleaving Aβ at three peptide bonds (Phe19-Phe20, Phe20-Ala21, and Leu34-Met35, with Leu34-Met35 being the initial and principal site); BACE2 catalytic efficiency exceeds all known Aβ-degrading proteases except IDE; BACE2 overexpression in cultured cells lowers net Aβ levels comparably to IDE and greater than neprilysin or ECE1.","method":"Genome-scale cDNA screen, in vitro Aβ degradation assay, catalytic efficiency measurement, cell-based Aβ lowering assay","journal":"Molecular neurodegeneration","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assay with cleavage site mapping and catalytic efficiency measurement, plus cell-based validation, single lab with multiple orthogonal methods","pmids":["22986058"],"is_preprint":false},{"year":2013,"finding":"BACE2 processes PMEL (melanocyte protein) by cleaving its integral membrane form within the juxtamembrane domain, releasing the PMEL luminal domain into endosomal precursors for amyloid fibril formation and melanosome morphogenesis; Bace2-/- but not Bace1-/- mice display coat color defects; confirmed using RNA silencing, pharmacologic inhibition, and BACE2 overexpression in human melanocytic cell lines.","method":"Bace2 knockout mice, RNA silencing, pharmacological inhibition, BACE2 overexpression, biochemical and morphological analyses of melanocytes","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic KO mouse, RNA silencing, pharmacological inhibition, and overexpression all converging on same substrate and phenotype; multiple orthogonal methods","pmids":["23754390"],"is_preprint":false},{"year":2013,"finding":"Systematic proteomic analysis of BACE2 substrates in pancreatic β-cells identified SEZ6L and SEZ6L2 (seizure 6 protein family members) as specific BACE2 substrates; BACE2 regulates a distinct, β-cell-enriched set of ectodomain shedding targets, non-redundant with BACE1 substrates.","method":"Quantitative proteomics (loss- and gain-of-function in vitro and in vivo models), mass spectrometry-based sheddome/secretome analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — systematic quantitative proteomics with both in vitro and in vivo loss/gain-of-function, multiple substrates identified","pmids":["23430253"],"is_preprint":false},{"year":2013,"finding":"BACE2 degradation is mediated by the macroautophagy-lysosome pathway (half-life ~20 h); lysosomal inhibition increased BACE2 protein levels while proteasomal inhibition had no effect; lysosomal inhibition also increased BACE2 cleavage of APP.","method":"Pharmacological inhibition of lysosomes and proteasomes, protein half-life measurement, APP processing assay","journal":"The European journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection of degradation pathway with functional consequence on APP cleavage, single lab","pmids":["23773066"],"is_preprint":false},{"year":2016,"finding":"Pharmacological inhibition of BACE2 (and BACE1) in mice inhibits PMEL17 proteolytic processing, leading to dose-dependent irreversible hair depigmentation; BACE2-mediated PMEL17 processing was confirmed in vitro in mouse and human melanocytes; bace2-/- mice show PMEL17 processing deficiency and hair depigmentation.","method":"Pharmacological inhibition (dual BACE1/2 inhibitor NB-360) in wild-type and bace2+/- and bace2-/- mice, in vitro melanocyte assays","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacological inhibition replicated across multiple genotypes in vivo plus in vitro validation in human and mouse melanocytes","pmids":["26912421"],"is_preprint":false},{"year":2016,"finding":"BACE2 cleaves human IAPP (islet amyloid polypeptide) at two distinct sites in the mature IAPP sequence; BACE2-mediated proteolysis modulates human IAPP fibrillation and leads to IAPP protein degradation.","method":"In vitro BACE2 cleavage assay with IAPP substrate, fibrillation assay, proteolysis mapping","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro cleavage assay with substrate site mapping, single lab, single method class","pmids":["26840340"],"is_preprint":false},{"year":2018,"finding":"BACE2 is expressed in discrete subsets of neurons and glia in the adult mouse brain; four new BACE2 substrates in cultured glia were identified: VCAM-1, DNER, FGFR1, and plexin domain containing 2; TNF induced a drastic increase in BACE2-mediated shedding of VCAM-1 in CSF under proinflammatory conditions.","method":"Immunohistochemistry of mouse brain, proteomics of conditioned media from BACE2 KO vs WT glia, TNF stimulation, CSF analysis","journal":"Life science alliance","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomic substrate identification with KO controls, TNF stimulation experiment, single lab","pmids":["30456346"],"is_preprint":false},{"year":2018,"finding":"BACE2 cleaves the potassium channel Kv2.1 at Thr376, Ala717, and Ser769, disrupting Kv2.1 clustering on the cell membrane, resulting in decreased delayed rectifier K+ current and a hyperpolarizing shift; cleaved Kv2.1 forms reduce the delayed rectifier surge and reduce neuronal apoptosis.","method":"Cell-based cleavage assays, electrophysiology, site-directed identification of cleavage sites, apoptosis assays in primary neurons","journal":"Molecular psychiatry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based cleavage site mapping combined with electrophysiology and apoptosis assays, single lab","pmids":["29703946"],"is_preprint":false},{"year":2018,"finding":"In zebrafish, Bace2 cleaves the insulin receptor as a sheddase in melanophores; loss of bace2 (wanderlust mutant) causes hyperdendritic, hyperproliferative melanophores with aberrant localization due to hyperactive insulin/PI3K/mTOR signaling; inhibition of insulin/PI3Kγ/mTOR signaling rescues the wanderlust phenotype.","method":"Zebrafish bace2 mutant (wanderlust), chemical suppressor screen, insulin receptor cleavage assay, epistasis analysis with PI3K/mTOR inhibitors","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic mutant with defined substrate (insulin receptor), chemical suppressor screen establishing pathway epistasis, single lab with multiple orthogonal methods","pmids":["29804876"],"is_preprint":false},{"year":2019,"finding":"BACE2 also processes APP at the beta-site; the juxtamembrane helix (JH) of APP normally inhibits BACE2 beta-secretase activity; JH-disrupting mutations and clusterin binding to JH trigger BACE2-mediated beta-cleavage of APP; both BACE2 and clusterin are elevated in aged mouse brains, enhancing beta-cleavage during aging.","method":"Cell-based APP cleavage assays with JH mutants, clusterin binding/co-IP, aged mouse brain biochemistry","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis of APP JH combined with co-IP of clusterin and in vivo aging data, single lab","pmids":["30626751"],"is_preprint":false},{"year":2010,"finding":"In pancreatic β-cells, BACE2 co-localizes with clathrin-coated vesicles at the plasma membrane; pharmacological inhibition or silencing of BACE2 increases BACE2 content in clathrin-coated vesicles, reduces insulin internalization rate, decreases insulin receptor β-subunit at the plasma membrane (increased in Golgi), and reduces insulin gene expression, indicating a role for BACE2 in insulin receptor trafficking.","method":"Immunofluorescence colocalization, pharmacological inhibition, siRNA silencing, insulin internalization assay, western blot of subcellular fractions","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic inhibition with subcellular localization and functional readouts, single lab","pmids":["20943756"],"is_preprint":false},{"year":2020,"finding":"BACE2 trisomy in Down syndrome is a gene dose-sensitive AD suppressor; CRISPR/Cas9 elimination of the third copy of BACE2 in trisomy 21 cerebral organoids triggered AD-like pathology (Aβ deposits, tau pathology, neuronal loss); T21 organoids secrete increased Aβ-preventing (Aβ1-19) and Aβ-degradation products (Aβ1-20, Aβ1-34); this protective mechanism is cross-inhibited by BACE1 inhibitors.","method":"CRISPR/Cas9 gene editing of trisomy 21 cerebral organoids, Aβ peptide profiling by mass spectrometry, CSF analysis in DS patients, BACE1 inhibitor treatment","journal":"Molecular psychiatry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — CRISPR gene editing in human organoid model with direct Aβ peptide profiling and CSF validation in human DS patients, multiple orthogonal approaches","pmids":["32647257"],"is_preprint":false},{"year":2024,"finding":"BACE2 is the protease responsible for shedding of the lymphangiogenic receptor VEGFR3 from lymphatic endothelial cells; BACE2 (not BACE1) inactivation inhibited VEGFR3 shedding from primary human lymphatic endothelial cells, reduced soluble VEGFR3 in blood of mice, non-human primates, and humans, and increased full-length VEGFR3 and VEGFR3 signaling; in zebrafish, BACE2 inactivation enhanced LEC migration; soluble VEGFR3 can serve as pharmacodynamic plasma marker for BACE2 activity.","method":"Genetic and pharmacological BACE2 inactivation in primary human LECs, mouse/NHP/human plasma sVEGFR3 measurement, zebrafish LEC migration assay, VEGFR3 signaling analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic and pharmacological inhibition in multiple species (mouse, NHP, human, zebrafish) with biochemical and functional readouts, independently validated in vivo and in vitro","pmids":["38888964"],"is_preprint":false},{"year":2013,"finding":"Multiple high-resolution crystal structures of BACE2 in six different packing environments were obtained using surface mutagenesis and co-crystallization with Fab fragments, Fynomers, and Xaperones; these structures define an ensemble of low-energy conformations accessible to the enzyme.","method":"X-ray crystallography with multiple crystallization helpers (Fab, Fynomers, Xaperones, surface mutagenesis)","journal":"Acta crystallographica. Section D, Biological crystallography","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple independent crystal structures in six packing environments, rigorous structural study","pmids":["23695257"],"is_preprint":false},{"year":2010,"finding":"In rat astrocytes, beta-secretase activity and Aβ production are due to BACE2 (not BACE1), whose expression is blocked at the translational level in astrocytes; neuroinflammatory changes can both positively and negatively modulate BACE2-dependent beta-secretase activity in astrocytes.","method":"Primary astrocyte cultures, translational regulation analysis, Aβ production assay, proinflammatory stimulation","journal":"The European journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — primary cell culture with mechanistic dissection of translational block and functional Aβ production, single lab","pmids":["21073551"],"is_preprint":false},{"year":2021,"finding":"BACE2 overexpression in ocular melanoma cells inhibits tumor progression in vitro and in vivo; BACE2 regulates TMEM38B expression, and the BACE2/TMEM38B axis modulates calcium release from the endoplasmic reticulum; increased N6-methyladenosine (m6A) RNA methylation leads to upregulation of BACE2 mRNA in ocular melanoma.","method":"BACE2 knockdown/overexpression in cell lines and xenografts, TMEM38B expression analysis, calcium flux assay, m6A methylation analysis","journal":"Molecular therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss/gain-of-function in vitro and in vivo with pathway substrate (TMEM38B/calcium) identified, single lab","pmids":["33601055"],"is_preprint":false},{"year":2022,"finding":"BACE2 loss-of-function mutation (BACE2G446R) in human pluripotent stem cell-derived brain organoids causes increased apoptosis and elevated Aβ oligomers resembling AD phenotypes; these phenotypes are rescued by APP removal; BACE2WT overexpression in organoids carrying APP Swedish/Indiana mutations attenuates Aβ accumulation and neuronal cell death.","method":"hPSC-derived brain organoids with BACE2 loss-of-function variant, CRISPR/APP knockout rescue, BACE2 overexpression in AD mutant organoids","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — human organoid model with loss-of-function and gain-of-function rescue experiments, single lab","pmids":["35110536"],"is_preprint":false},{"year":2005,"finding":"BACE2 knockout mice display an overall healthy phenotype; combined BACE1/BACE2 deficiency enhances BACE1-/- lethality; BACE2 contributes to Aβ generation in glia (which lack BACE1 activity), not in neurons.","method":"Genetic knockout mice (single and double KO), biochemical Aβ analysis in neurons and glia","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO mouse models (single and double) with biochemical Aβ analysis and cell-type-specific dissection, replicated in vivo","pmids":["15987683"],"is_preprint":false},{"year":2013,"finding":"In zebrafish, loss of Bace2 results in a specific melanocyte migration and morphology phenotype not observed in Bace1-/- fish; double homozygous bace1-/-; bace2-/- fish do not enhance single mutant phenotypes, indicating non-redundant, distinct physiological functions for Bace1 and Bace2.","method":"Zinc finger nuclease-mediated gene editing to generate Bace1 and Bace2 KO zebrafish, phenotypic analysis of single and double mutants","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO and double-KO zebrafish with defined non-redundant phenotypes, single lab","pmids":["23406323"],"is_preprint":false}],"current_model":"BACE2 is a membrane-anchored aspartyl protease that undergoes autocatalytic prodomain removal in the ER/Golgi and traffics through TGN, endosomes, and plasma membrane; it cleaves multiple substrates including APP (primarily at the Phe19-Phe20 theta-site to suppress Aβ production, but also conditionally at the beta-site), PMEL17 (releasing the luminal domain for functional amyloid fibril formation in melanosomes), Tmem27 (regulating pancreatic β-cell mass and glucose homeostasis), IAPP, Kv2.1 (reducing neuronal apoptosis), the insulin receptor (negatively regulating insulin/PI3K/mTOR signaling in melanophores), VEGFR3 (modulating lymphangiogenic signaling), and additional glial substrates (VCAM-1, DNER, FGFR1, SEZ6L/SEZ6L2) that become prominent under proinflammatory TNF stimulation."},"narrative":{"mechanistic_narrative":"BACE2 is a membrane-anchored aspartyl protease of the A1 family that functions as a regulated ectodomain sheddase, processing a diverse set of transmembrane substrates across the secretory and endosomal pathways [PMID:16305800, PMID:10683441]. It matures by autocatalytic removal of its prodomain (cleavage between Leu62 and Ala63) within the ER/early Golgi, a step abolished by mutation of the catalytic aspartate (D110N), after which mature enzyme traffics through ER, Golgi, TGN, endosomes, and the plasma membrane in a transmembrane-domain-dependent manner [PMID:11316808, PMID:11423558]. Its crystal structure confirms the canonical aspartic-protease fold with an enlarged C-terminal domain and active-site pockets (S3, S2, S1', S2') distinct from BACE1, and the enzyme samples an ensemble of low-energy conformations [PMID:16305800, PMID:23695257]. On APP, BACE2 acts principally as an anti-amyloidogenic protease, cleaving within the Aβ domain at the theta site (Phe19-Phe20) to raise sAPP/p3-like products and suppress Aβ, while retaining conditional beta-site activity that is normally restrained by the APP juxtamembrane helix and unmasked by clusterin binding during aging [PMID:12065613, PMID:16816112, PMID:30626751]; it additionally degrades Aβ peptide directly with catalytic efficiency rivaling IDE [PMID:22986058]. This protective function is gene-dose sensitive: BACE2 trisomy suppresses Alzheimer-like pathology in Down syndrome organoids, and loss-of-function variants drive Aβ-dependent neuronal death [PMID:32647257, PMID:35110536]. Beyond the brain, BACE2 sheds Tmem27 to control pancreatic β-cell mass and glucose homeostasis, processes the melanosomal protein PMEL to enable functional amyloid fibril formation and pigmentation, cleaves the lymphangiogenic receptor VEGFR3 to limit its signaling, and acts on the insulin receptor, Kv2.1, IAPP, and glial substrates including SEZ6L/SEZ6L2 and VCAM-1 under inflammatory conditions [PMID:21907142, PMID:23754390, PMID:38888964, PMID:29804876, PMID:29703946, PMID:26840340, PMID:23430253, PMID:30456346]. Genetic ablation in mice and zebrafish yields viable animals with pigmentation and melanophore phenotypes non-redundant with BACE1 [PMID:23754390, PMID:15987683, PMID:23406323].","teleology":[{"year":2000,"claim":"Establishing that BACE2 is a membrane-anchored aspartic protease capable of cleaving APP defined the enzyme's basic biochemical identity and placed it alongside BACE1 as a candidate amyloidogenic protease.","evidence":"In vitro translation, cell transfection, glycosylation analysis, and cell-based cleavage/active-site mutagenesis assays on APP","pmids":["10683441","10931940"],"confidence":"High","gaps":["Did not resolve whether net effect on Aβ is amyloidogenic or anti-amyloidogenic","Physiological substrates beyond APP unknown"]},{"year":2001,"claim":"Defining the autocatalytic prodomain cleavage site and showing BACE2 acts mainly within the Aβ domain rather than at the beta-site reframed its role as an alternative alpha/theta-secretase and clarified its maturation and trafficking.","evidence":"D110N active-site mutagenesis, fusion-protein and synthetic-peptide cleavage assays, cell fractionation, and subcellular localization with TM-domain chimeras","pmids":["11316808","11423558"],"confidence":"High","gaps":["Compartment in which physiologically relevant cleavage occurs not fully resolved","Regulation of trafficking not defined"]},{"year":2002,"claim":"Direct radiosequencing pinned the APP cleavage to Phe19-Phe20 within the Aβ domain, biochemically proving BACE2 suppresses rather than generates Aβ.","evidence":"Radiosequencing of membrane-bound C-terminal cleavage products with compartment-specific cell-based processing","pmids":["12065613"],"confidence":"High","gaps":["Whether this anti-amyloidogenic activity operates in vivo in human brain untested at this stage"]},{"year":2005,"claim":"Crystallization of mature BACE2 with a transition-state inhibitor provided the structural basis for active-site differences from BACE1, enabling rational inhibitor and selectivity considerations.","evidence":"X-ray crystallography at 3.1 Å of autocatalytically activated, refolded recombinant BACE2","pmids":["16305800"],"confidence":"High","gaps":["No substrate-bound structure","Conformational dynamics not captured by single structure"]},{"year":2005,"claim":"Knockout mice and cell-type analysis showed BACE2 is dispensable for normal development but contributes to glial (not neuronal) Aβ generation, distinguishing it physiologically from BACE1.","evidence":"Single and double BACE1/BACE2 knockout mice with biochemical Aβ analysis in neurons and glia","pmids":["15987683"],"confidence":"High","gaps":["Physiological substrate underlying any phenotype not identified here","Cell-type basis of glial-specific activity unexplained"]},{"year":2011,"claim":"Identification of Tmem27 as a BACE2 substrate established a non-neural physiological role controlling pancreatic β-cell mass and glucose homeostasis, opening BACE2 as a metabolic drug target.","evidence":"siRNA screen, genetic knockout mice, pharmacological inhibition with β-cell mass and glucose readouts; substrate structural requirements defined by mutagenesis and biochemistry","pmids":["21907142","22628310"],"confidence":"High","gaps":["Mechanism linking Tmem27 shedding to proliferation incomplete","Translation of inhibitor metabolic effects to humans untested"]},{"year":2012,"claim":"Demonstration that BACE2 directly degrades Aβ peptide with IDE-like efficiency added a second anti-amyloidogenic mechanism beyond protective APP cleavage.","evidence":"Genome-scale cDNA screen, in vitro Aβ degradation with cleavage-site mapping and catalytic efficiency measurement, cell-based Aβ lowering","pmids":["22986058"],"confidence":"High","gaps":["In vivo contribution of Aβ degradation versus APP cleavage not quantified","Cellular site of Aβ degradation unclear"]},{"year":2013,"claim":"Identification of PMEL processing and SEZ6L/SEZ6L2 shedding defined BACE2's physiological substrate repertoire in melanosomes and β-cells, explaining pigmentation phenotypes and tissue-specific, non-redundant function.","evidence":"Bace2 knockout mice, RNA silencing, pharmacologic inhibition, overexpression, and quantitative sheddome proteomics; additional crystal structures defining conformational ensemble","pmids":["23754390","23430253","23695257"],"confidence":"High","gaps":["Full substrate spectrum across tissues not exhaustively mapped","Signaling consequences of SEZ6L family shedding unresolved"]},{"year":2013,"claim":"Non-redundant phenotypes in zebrafish and definition of BACE2 turnover via macroautophagy clarified its distinct biology and a route for regulating its abundance and activity.","evidence":"Zinc-finger-nuclease KO and double-KO zebrafish phenotyping; pharmacological lysosome/proteasome inhibition with half-life and APP-cleavage readouts","pmids":["23406323","23773066"],"confidence":"High","gaps":["Signals targeting BACE2 to lysosomal degradation unknown","Relationship of zebrafish melanocyte phenotype to mammalian substrates partial"]},{"year":2016,"claim":"Pharmacological inhibition causing irreversible hair depigmentation linked on-target BACE2 PMEL processing to a defined safety/biomarker consequence of BACE inhibitors.","evidence":"Dual BACE1/2 inhibitor across wild-type and bace2 genotypes in vivo plus in vitro melanocyte validation; in vitro IAPP cleavage/fibrillation mapping","pmids":["26912421","26840340"],"confidence":"High","gaps":["IAPP cleavage shown only in vitro, physiological relevance unestablished","Reversibility/mechanism of pigmentation loss incomplete"]},{"year":2018,"claim":"Discovery of insulin receptor, Kv2.1, and glial inflammatory substrates broadened BACE2's signaling reach into PI3K/mTOR control, neuronal excitability/apoptosis, and neuroinflammation.","evidence":"Zebrafish bace2 mutant with chemical suppressor epistasis; cell-based Kv2.1 cleavage mapping with electrophysiology and apoptosis assays; glial sheddome proteomics with TNF stimulation","pmids":["29804876","29703946","30456346"],"confidence":"Medium","gaps":["Mammalian relevance of zebrafish insulin-receptor shedding untested","Physiological role of inflammation-induced VCAM-1 shedding undefined"]},{"year":2019,"claim":"Showing that the APP juxtamembrane helix restrains BACE2 beta-cleavage and that clusterin/aging unmask it provided a conditional switch converting BACE2 from protective to amyloidogenic.","evidence":"Cell-based APP cleavage assays with JH mutants, clusterin co-IP, and aged mouse brain biochemistry","pmids":["30626751"],"confidence":"Medium","gaps":["Quantitative contribution of this switch to age-related amyloidogenesis unknown","Structural basis of clusterin-JH interaction not resolved"]},{"year":2020,"claim":"Gene-dose experiments in human trisomy 21 organoids established BACE2 as a dose-sensitive Alzheimer suppressor and revealed cross-inhibition of its protective activity by BACE1 inhibitors.","evidence":"CRISPR/Cas9 editing of trisomy 21 cerebral organoids, Aβ peptide profiling by mass spectrometry, DS CSF analysis, BACE1 inhibitor treatment; complementary LOF-variant organoid rescue by APP removal","pmids":["32647257","35110536"],"confidence":"High","gaps":["Whether BACE2 enhancement is therapeutically tractable untested","In vivo human relevance beyond organoid/CSF data limited"]},{"year":2024,"claim":"Identifying VEGFR3 as a BACE2-specific shed substrate connected the enzyme to lymphangiogenic signaling and provided soluble VEGFR3 as a translational pharmacodynamic marker of BACE2 activity.","evidence":"Genetic and pharmacological BACE2 inactivation in human LECs, plasma sVEGFR3 measurement in mouse/NHP/human, zebrafish LEC migration, VEGFR3 signaling analysis","pmids":["38888964"],"confidence":"High","gaps":["Physiological/pathological consequences of altered lymphangiogenesis upon chronic inhibition unclear","Tissue specificity of VEGFR3 shedding not mapped"]},{"year":null,"claim":"How BACE2 substrate selection and the protective-versus-amyloidogenic balance are coordinated across tissues, trafficking compartments, and disease states remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of how compartmental localization dictates which substrate is cleaved","Regulators that toggle theta- versus beta-site APP cleavage in vivo unknown","Therapeutic window separating protective Aβ effects from pigmentation/metabolic/lymphatic on-target liabilities undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,5,10,13,19,24]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[3,7,12]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,3,4,22]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[2,4,5]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[3,4]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[4]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[22]}],"pathway":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,5]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,10,13,24]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[23,28]}],"complexes":[],"partners":["APP","TMEM27","PMEL","VEGFR3","KCNB1","INSR","SEZ6L","VCAM1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9Y5Z0","full_name":"Beta-secretase 2","aliases":["Aspartic-like protease 56 kDa","Aspartyl protease 1","ASP1","Asp 1","Beta-site amyloid precursor protein cleaving enzyme 2","Beta-site APP cleaving enzyme 2","Down region aspartic protease","DRAP","Memapsin-1","Membrane-associated aspartic protease 1","Theta-secretase"],"length_aa":518,"mass_kda":56.2,"function":"Responsible for the proteolytic processing of the amyloid precursor protein (APP). Cleaves APP, between residues 690 and 691, leading to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase. It has also been shown that it can cleave APP between residues 671 and 672 (PubMed:10591213, PubMed:11083922, PubMed:11423558, PubMed:15857888, PubMed:16816112). Involved in the proteolytic shedding of PMEL at early stages of melanosome biogenesis. Cleaves PMEL within the M-beta fragment to release the amyloidogenic PMEL luminal fragment containing M-alpha and a small portion of M-beta N-terminus. This is a prerequisite step for subsequent processing and assembly of PMEL fibrils into amyloid sheets (PubMed:23754390). Responsible also for the proteolytic processing of CLTRN in pancreatic beta cells (PubMed:21907142)","subcellular_location":"Cell membrane; Golgi apparatus; Endoplasmic reticulum; Endosome; Melanosome","url":"https://www.uniprot.org/uniprotkb/Q9Y5Z0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BACE2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BACE2","total_profiled":1310},"omim":[{"mim_id":"617221","title":"HEXOKINASE DOMAIN-CONTAINING PROTEIN 1; HKDC1","url":"https://www.omim.org/entry/617221"},{"mim_id":"605668","title":"BETA-SITE AMYLOID BETA A4 PRECURSOR PROTEIN-CLEAVING ENZYME 2; BACE2","url":"https://www.omim.org/entry/605668"},{"mim_id":"604252","title":"BETA-SITE AMYLOID BETA A4 PRECURSOR PROTEIN-CLEAVING ENZYME 1; BACE1","url":"https://www.omim.org/entry/604252"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"stomach 1","ntpm":21.6}],"url":"https://www.proteinatlas.org/search/BACE2"},"hgnc":{"alias_symbol":["ASP1","DRAP","ALP56","CEAP1"],"prev_symbol":["AEPLC"]},"alphafold":{"accession":"Q9Y5Z0","domains":[{"cath_id":"2.40.70.10","chopping":"93-225","consensus_level":"medium","plddt":96.9507,"start":93,"end":225},{"cath_id":"2.40.70.10","chopping":"227-470","consensus_level":"medium","plddt":92.1436,"start":227,"end":470}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y5Z0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y5Z0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y5Z0-F1-predicted_aligned_error_v6.png","plddt_mean":82.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BACE2","jax_strain_url":"https://www.jax.org/strain/search?query=BACE2"},"sequence":{"accession":"Q9Y5Z0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y5Z0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y5Z0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y5Z0"}},"corpus_meta":[{"pmid":"10931940","id":"PMC_10931940","title":"BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10931940","citation_count":340,"is_preprint":false},{"pmid":"15987683","id":"PMC_15987683","title":"Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15987683","citation_count":297,"is_preprint":false},{"pmid":"7876316","id":"PMC_7876316","title":"The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor.","date":"1995","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7876316","citation_count":267,"is_preprint":false},{"pmid":"10749877","id":"PMC_10749877","title":"Expression analysis of BACE2 in brain and peripheral tissues.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10749877","citation_count":252,"is_preprint":false},{"pmid":"23754390","id":"PMC_23754390","title":"BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23754390","citation_count":154,"is_preprint":false},{"pmid":"11423558","id":"PMC_11423558","title":"BACE2 functions as an alternative alpha-secretase in cells.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11423558","citation_count":149,"is_preprint":false},{"pmid":"11083922","id":"PMC_11083922","title":"ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site.","date":"2000","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/11083922","citation_count":147,"is_preprint":false},{"pmid":"16816112","id":"PMC_16816112","title":"BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome.","date":"2006","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/16816112","citation_count":142,"is_preprint":false},{"pmid":"21907142","id":"PMC_21907142","title":"Bace2 is a β cell-enriched protease that regulates pancreatic β cell function and mass.","date":"2011","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21907142","citation_count":126,"is_preprint":false},{"pmid":"15857888","id":"PMC_15857888","title":"Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes.","date":"2005","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/15857888","citation_count":118,"is_preprint":false},{"pmid":"10683441","id":"PMC_10683441","title":"The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region.","date":"2000","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10683441","citation_count":117,"is_preprint":false},{"pmid":"19968762","id":"PMC_19968762","title":"BACE1 and BACE2 enzymatic activities in Alzheimer's disease.","date":"2009","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19968762","citation_count":101,"is_preprint":false},{"pmid":"32647257","id":"PMC_32647257","title":"Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain.","date":"2020","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/32647257","citation_count":97,"is_preprint":false},{"pmid":"23773065","id":"PMC_23773065","title":"Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.","date":"2013","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23773065","citation_count":93,"is_preprint":false},{"pmid":"12065613","id":"PMC_12065613","title":"A non-amyloidogenic function of BACE-2 in the secretory pathway.","date":"2002","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12065613","citation_count":93,"is_preprint":false},{"pmid":"14976610","id":"PMC_14976610","title":"Cloning, yeast expression, isolation, and vaccine testing of recombinant Ancylostoma-secreted protein (ASP)-1 and ASP-2 from Ancylostoma ceylanicum.","date":"2004","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/14976610","citation_count":93,"is_preprint":false},{"pmid":"23430253","id":"PMC_23430253","title":"Systematic proteomic analysis identifies β-site amyloid precursor protein cleaving enzyme 2 and 1 (BACE2 and BACE1) substrates in pancreatic β-cells.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23430253","citation_count":81,"is_preprint":false},{"pmid":"15473697","id":"PMC_15473697","title":"Insights from modeling the tertiary structure of human BACE2.","date":"2004","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/15473697","citation_count":79,"is_preprint":false},{"pmid":"30626751","id":"PMC_30626751","title":"BACE2, a conditional β-secretase, contributes to Alzheimer's disease pathogenesis.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/30626751","citation_count":71,"is_preprint":false},{"pmid":"10965118","id":"PMC_10965118","title":"A new aspartyl protease on 21q22.3, BACE2, is highly similar to Alzheimer's amyloid precursor protein beta-secretase.","date":"2000","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10965118","citation_count":71,"is_preprint":false},{"pmid":"31545898","id":"PMC_31545898","title":"Molecular Mechanism of Binding Selectivity of Inhibitors toward BACE1 and BACE2 Revealed by Multiple Short Molecular Dynamics Simulations and Free-Energy Predictions.","date":"2019","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31545898","citation_count":66,"is_preprint":false},{"pmid":"26912421","id":"PMC_26912421","title":"Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26912421","citation_count":60,"is_preprint":false},{"pmid":"12736275","id":"PMC_12736275","title":"BACE1- and BACE2-expressing human cells: characterization of beta-amyloid precursor protein-derived catabolites, design of a novel fluorimetric assay, and identification of new in vitro inhibitors.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12736275","citation_count":60,"is_preprint":false},{"pmid":"26795495","id":"PMC_26795495","title":"Bacillus thuringiensis Crystal Protein Cry6Aa Triggers Caenorhabditis elegans Necrosis Pathway Mediated by Aspartic Protease (ASP-1).","date":"2016","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/26795495","citation_count":58,"is_preprint":false},{"pmid":"17511655","id":"PMC_17511655","title":"The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.","date":"2007","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/17511655","citation_count":55,"is_preprint":false},{"pmid":"23406323","id":"PMC_23406323","title":"Loss of Bace2 in zebrafish affects melanocyte migration and is distinct from Bace1 knock out phenotypes.","date":"2013","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23406323","citation_count":55,"is_preprint":false},{"pmid":"30456346","id":"PMC_30456346","title":"BACE2 distribution in major brain cell types and identification of novel substrates.","date":"2018","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/30456346","citation_count":54,"is_preprint":false},{"pmid":"10854422","id":"PMC_10854422","title":"Aspartic proteases from the nematode Caenorhabditis elegans. Structural organization and developmental and cell-specific expression of asp-1.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10854422","citation_count":54,"is_preprint":false},{"pmid":"22074738","id":"PMC_22074738","title":"BACE2 expression increases in human neurodegenerative disease.","date":"2011","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22074738","citation_count":53,"is_preprint":false},{"pmid":"22986058","id":"PMC_22986058","title":"Identification of BACE2 as an avid ß-amyloid-degrading protease.","date":"2012","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/22986058","citation_count":53,"is_preprint":false},{"pmid":"172631","id":"PMC_172631","title":"Synthesis and evaluation of (Des-Asp1)angiotensin I as a precursor for (Des-Asp1)angiotensin II (\"Angiotensin III\").","date":"1975","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/172631","citation_count":51,"is_preprint":false},{"pmid":"29440310","id":"PMC_29440310","title":"Asp1 Bifunctional Activity Modulates Spindle Function via Controlling Cellular Inositol Pyrophosphate Levels in Schizosaccharomyces pombe.","date":"2018","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29440310","citation_count":48,"is_preprint":false},{"pmid":"17113083","id":"PMC_17113083","title":"Altered beta-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer's disease brain.","date":"2006","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/17113083","citation_count":45,"is_preprint":false},{"pmid":"10049587","id":"PMC_10049587","title":"Cloning of Aire, the mouse homologue of the autoimmune regulator (AIRE) gene responsible for autoimmune polyglandular syndrome type 1 (ASP1).","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10049587","citation_count":42,"is_preprint":false},{"pmid":"16305800","id":"PMC_16305800","title":"Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor.","date":"2005","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16305800","citation_count":41,"is_preprint":false},{"pmid":"11435901","id":"PMC_11435901","title":"Association studies using novel polymorphisms in BACE1 and BACE2.","date":"2001","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/11435901","citation_count":41,"is_preprint":false},{"pmid":"20624911","id":"PMC_20624911","title":"Asp1, a conserved 1/3 inositol polyphosphate kinase, regulates the dimorphic switch in Schizosaccharomyces pombe.","date":"2010","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20624911","citation_count":40,"is_preprint":false},{"pmid":"178468","id":"PMC_178468","title":"Evidence that des-Asp1 angiotensin II mediates the renin-angiotensin response.","date":"1976","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/178468","citation_count":40,"is_preprint":false},{"pmid":"12895444","id":"PMC_12895444","title":"BACE-2 is overexpressed in Down's syndrome.","date":"2003","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12895444","citation_count":39,"is_preprint":false},{"pmid":"187407","id":"PMC_187407","title":"(Des-Asp1) angiotensin I: a study of its pressor and steroidogenic activities in conscious rats.","date":"1977","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/187407","citation_count":39,"is_preprint":false},{"pmid":"11747923","id":"PMC_11747923","title":"Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis.","date":"2001","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/11747923","citation_count":39,"is_preprint":false},{"pmid":"26422458","id":"PMC_26422458","title":"Asp1 from Schizosaccharomyces pombe binds a [2Fe-2S](2+) cluster which inhibits inositol pyrophosphate 1-phosphatase activity.","date":"2015","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26422458","citation_count":38,"is_preprint":false},{"pmid":"321257","id":"PMC_321257","title":"[Des-Asp1] angiotensin II: mediator of the renin-angiotensin system?","date":"1977","source":"Federation proceedings","url":"https://pubmed.ncbi.nlm.nih.gov/321257","citation_count":38,"is_preprint":false},{"pmid":"12618121","id":"PMC_12618121","title":"BACE1 and BACE2 in pathologic and normal human muscle.","date":"2003","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12618121","citation_count":37,"is_preprint":false},{"pmid":"178463","id":"PMC_178463","title":"The effects of des-Asp1-angiotensin II on blood pressure, plasma aldosterone concentration, and plasma renin activity in the rabbit.","date":"1976","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/178463","citation_count":37,"is_preprint":false},{"pmid":"20943756","id":"PMC_20943756","title":"BACE2 plays a role in the insulin receptor trafficking in pancreatic ß-cells.","date":"2010","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20943756","citation_count":35,"is_preprint":false},{"pmid":"24462566","id":"PMC_24462566","title":"Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome.","date":"2013","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/24462566","citation_count":35,"is_preprint":false},{"pmid":"2357530","id":"PMC_2357530","title":"Intracerebroventricularly infused [D-Arg1]angiotensin III, is superior to [D-Asp1]angiotensin II, as a pressor agent in rats.","date":"1990","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/2357530","citation_count":35,"is_preprint":false},{"pmid":"11316808","id":"PMC_11316808","title":"Prodomain processing of Asp1 (BACE2) is autocatalytic.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11316808","citation_count":34,"is_preprint":false},{"pmid":"8093092","id":"PMC_8093092","title":"Degradation of angiotensin I to [des-Asp1]angiotensin I by a novel aminopeptidase in the rat hypothalamus.","date":"1994","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8093092","citation_count":34,"is_preprint":false},{"pmid":"19298387","id":"PMC_19298387","title":"Allosteric and binding properties of Asp1-Glu382 truncated recombinant human serum albumin--an optical and NMR spectroscopic investigation.","date":"2009","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/19298387","citation_count":33,"is_preprint":false},{"pmid":"10388810","id":"PMC_10388810","title":"Identification and characterization of Schizosaccharomyces pombe asp1(+), a gene that interacts with mutations in the Arp2/3 complex and actin.","date":"1999","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10388810","citation_count":32,"is_preprint":false},{"pmid":"12739891","id":"PMC_12739891","title":"Transfer and expression of an artificial storage protein (ASP1) gene in cassava (Manihot esculenta Crantz).","date":"2003","source":"Transgenic research","url":"https://pubmed.ncbi.nlm.nih.gov/12739891","citation_count":31,"is_preprint":false},{"pmid":"26840340","id":"PMC_26840340","title":"Identification of Human Islet Amyloid Polypeptide as a BACE2 Substrate.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26840340","citation_count":31,"is_preprint":false},{"pmid":"33601055","id":"PMC_33601055","title":"m6A RNA hypermethylation-induced BACE2 boosts intracellular calcium release and accelerates tumorigenesis of ocular melanoma.","date":"2021","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33601055","citation_count":30,"is_preprint":false},{"pmid":"31589043","id":"PMC_31589043","title":"Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2.","date":"2019","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31589043","citation_count":30,"is_preprint":false},{"pmid":"31021626","id":"PMC_31021626","title":"Structure-Based Design of Selective β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2.","date":"2019","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31021626","citation_count":29,"is_preprint":false},{"pmid":"20732469","id":"PMC_20732469","title":"Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.","date":"2010","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/20732469","citation_count":29,"is_preprint":false},{"pmid":"35110536","id":"PMC_35110536","title":"BACE2 variant identified from HSCR patient causes AD-like phenotypes in hPSC-derived brain organoids.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35110536","citation_count":28,"is_preprint":false},{"pmid":"21073551","id":"PMC_21073551","title":"β-Secretase activity in rat astrocytes: translational block of BACE1 and modulation of BACE2 expression.","date":"2010","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21073551","citation_count":28,"is_preprint":false},{"pmid":"16023140","id":"PMC_16023140","title":"Chromosome 21 BACE2 haplotype associates with Alzheimer's disease: a two-stage study.","date":"2005","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16023140","citation_count":27,"is_preprint":false},{"pmid":"33413577","id":"PMC_33413577","title":"Cell surface GRP78 regulates BACE2 via lysosome-dependent manner to maintain mesenchymal phenotype of glioma stem cells.","date":"2021","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/33413577","citation_count":26,"is_preprint":false},{"pmid":"16757811","id":"PMC_16757811","title":"Functional domains of the BACE1 and BACE2 promoters and mechanisms of transcriptional suppression of the BACE2 promoter in normal neuronal cells.","date":"2006","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/16757811","citation_count":25,"is_preprint":false},{"pmid":"10513681","id":"PMC_10513681","title":"Behavioural and histological effects of atrazine on freshwater molluscs (Physa acuta Drap. and Ancylus fluviatilis Müll. Gastropoda).","date":"1999","source":"Journal of applied toxicology : JAT","url":"https://pubmed.ncbi.nlm.nih.gov/10513681","citation_count":24,"is_preprint":false},{"pmid":"29703946","id":"PMC_29703946","title":"Cleavage of potassium channel Kv2.1 by BACE2 reduces neuronal apoptosis.","date":"2018","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/29703946","citation_count":24,"is_preprint":false},{"pmid":"25195542","id":"PMC_25195542","title":"Binding interaction between a queen pheromone component HOB and pheromone binding protein ASP1 of Apis cerana.","date":"2014","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/25195542","citation_count":24,"is_preprint":false},{"pmid":"196831","id":"PMC_196831","title":"Stimulation of corticosteroid biosynthesis by angiotensin I [des-asp1]angiotensin I, angiotensin II and [des-asp1]-angiotensin II in bovine adrenal fasciculata cells.","date":"1977","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/196831","citation_count":24,"is_preprint":false},{"pmid":"23695257","id":"PMC_23695257","title":"Mapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and Xaperones.","date":"2013","source":"Acta crystallographica. Section D, Biological crystallography","url":"https://pubmed.ncbi.nlm.nih.gov/23695257","citation_count":24,"is_preprint":false},{"pmid":"18086018","id":"PMC_18086018","title":"Vaccine testing of a recombinant activation-associated secreted protein (ASP1) from Ostertagia ostertagi.","date":"2008","source":"Parasite immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18086018","citation_count":24,"is_preprint":false},{"pmid":"12005423","id":"PMC_12005423","title":"Disulfide pairing and secondary structure of ASP1, an olfactory-binding protein from honeybee (Apis mellifera L).","date":"2001","source":"The journal of peptide research : official journal of the American Peptide Society","url":"https://pubmed.ncbi.nlm.nih.gov/12005423","citation_count":23,"is_preprint":false},{"pmid":"7350186","id":"PMC_7350186","title":"Biological activity of des-Asp1-angiotensin I in man.","date":"1980","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/7350186","citation_count":23,"is_preprint":false},{"pmid":"23519657","id":"PMC_23519657","title":"Structure of Ostertagia ostertagi ASP-1: insights into disulfide-mediated cyclization and dimerization.","date":"2013","source":"Acta crystallographica. Section D, Biological crystallography","url":"https://pubmed.ncbi.nlm.nih.gov/23519657","citation_count":23,"is_preprint":false},{"pmid":"954820","id":"PMC_954820","title":"Des-Asp1-angiotensin I: a metabolite of angiotensin I in the perfused feline adrenal.","date":"1976","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/954820","citation_count":23,"is_preprint":false},{"pmid":"19840121","id":"PMC_19840121","title":"Characterization of a mouse model overexpressing beta-site APP-cleaving enzyme 2 reveals a new role for BACE2.","date":"2009","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/19840121","citation_count":22,"is_preprint":false},{"pmid":"29199322","id":"PMC_29199322","title":"Reversible and Species-Specific Depigmentation Effects of AZD3293, a BACE Inhibitor for the Treatment of Alzheimer's Disease, Are Related to BACE2 Inhibition and Confined to Epidermis and Hair.","date":"2016","source":"The journal of prevention of Alzheimer's disease","url":"https://pubmed.ncbi.nlm.nih.gov/29199322","citation_count":21,"is_preprint":false},{"pmid":"31079034","id":"PMC_31079034","title":"Transcriptional Corepressor ASP1 and CLV-Like Signaling Regulate Meristem Maintenance in Rice.","date":"2019","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31079034","citation_count":20,"is_preprint":false},{"pmid":"23506624","id":"PMC_23506624","title":"BACE2 as a new diabetes target: a patent review (2010 - 2012).","date":"2013","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/23506624","citation_count":19,"is_preprint":false},{"pmid":"23773066","id":"PMC_23773066","title":"BACE2 degradation mediated by the macroautophagy-lysosome pathway.","date":"2013","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23773066","citation_count":19,"is_preprint":false},{"pmid":"25342134","id":"PMC_25342134","title":"Inhibition of BACE2 counteracts hIAPP-induced insulin secretory defects in pancreatic β-cells.","date":"2014","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/25342134","citation_count":19,"is_preprint":false},{"pmid":"8026756","id":"PMC_8026756","title":"The ASP1 gene of Saccharomyces cerevisiae, encoding the intracellular isozyme of L-asparaginase.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8026756","citation_count":19,"is_preprint":false},{"pmid":"26804314","id":"PMC_26804314","title":"A comparative molecular dynamics study on BACE1 and BACE2 flap flexibility.","date":"2016","source":"Journal of receptor and signal transduction research","url":"https://pubmed.ncbi.nlm.nih.gov/26804314","citation_count":19,"is_preprint":false},{"pmid":"31270419","id":"PMC_31270419","title":"Common BACE2 Polymorphisms are Associated with Altered Risk for Alzheimer's Disease and CSF Amyloid Biomarkers in APOE ε4 Non-Carriers.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31270419","citation_count":19,"is_preprint":false},{"pmid":"20596738","id":"PMC_20596738","title":"In vivo effects of APP are not exacerbated by BACE2 co-overexpression: behavioural characterization of a double transgenic mouse model.","date":"2010","source":"Amino acids","url":"https://pubmed.ncbi.nlm.nih.gov/20596738","citation_count":19,"is_preprint":false},{"pmid":"28337562","id":"PMC_28337562","title":"BACE2 suppression promotes β-cell survival and function in a model of type 2 diabetes induced by human islet amyloid polypeptide overexpression.","date":"2017","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/28337562","citation_count":18,"is_preprint":false},{"pmid":"30637955","id":"PMC_30637955","title":"Highly Selective and Potent Human β-Secretase 2 (BACE2) Inhibitors against Type 2 Diabetes: Design, Synthesis, X-ray Structure and Structure-Activity Relationship Studies.","date":"2019","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/30637955","citation_count":18,"is_preprint":false},{"pmid":"29804876","id":"PMC_29804876","title":"Distant Insulin Signaling Regulates Vertebrate Pigmentation through the Sheddase Bace2.","date":"2018","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/29804876","citation_count":18,"is_preprint":false},{"pmid":"34436165","id":"PMC_34436165","title":"The PPIP5K Family Member Asp1 Controls Inorganic Polyphosphate Metabolism in S. pombe.","date":"2021","source":"Journal of fungi (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34436165","citation_count":18,"is_preprint":false},{"pmid":"744059","id":"PMC_744059","title":"Formation of DES-ASP1-angiotensin II is not an obligatory step in the steroidogenic action of angiotensin II in the canine adrenal.","date":"1978","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/744059","citation_count":18,"is_preprint":false},{"pmid":"36463454","id":"PMC_36463454","title":"BACE2: A Promising Neuroprotective Candidate for Alzheimer's Disease.","date":"2023","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/36463454","citation_count":17,"is_preprint":false},{"pmid":"464116","id":"PMC_464116","title":"Formation of angiotensin III from [des-Asp1]angiotensin I in the mesentric vasculature.","date":"1979","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/464116","citation_count":16,"is_preprint":false},{"pmid":"31031430","id":"PMC_31031430","title":"Isolation and Characterization of Multidrug Resistance Aeromonas salmonicida subsp. salmonicida and Its Infecting Novel Phage ASP-1 from Goldfish (Carassius auratus).","date":"2019","source":"Indian journal of microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/31031430","citation_count":16,"is_preprint":false},{"pmid":"22628310","id":"PMC_22628310","title":"Tmem27 dimerization, deglycosylation, plasma membrane depletion, and the extracellular Phe-Phe motif are negative regulators of cleavage by Bace2.","date":"2012","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22628310","citation_count":15,"is_preprint":false},{"pmid":"24381583","id":"PMC_24381583","title":"A tale of two drug targets: the evolutionary history of BACE1 and BACE2.","date":"2013","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24381583","citation_count":15,"is_preprint":false},{"pmid":"29291","id":"PMC_29291","title":"Correlation of the biological activity and solution conformation of [Asp1,Ile5]- and [Phe4,Tyr8]angiotensin II.","date":"1978","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29291","citation_count":15,"is_preprint":false},{"pmid":"27697865","id":"PMC_27697865","title":"Inositol Pyrophosphate Kinase Asp1 Modulates Chromosome Segregation Fidelity and Spindle Function in Schizosaccharomyces pombe.","date":"2016","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27697865","citation_count":14,"is_preprint":false},{"pmid":"25254246","id":"PMC_25254246","title":"Amino acid sequence and structural comparison of BACE1 and BACE2 using evolutionary trace method.","date":"2014","source":"TheScientificWorldJournal","url":"https://pubmed.ncbi.nlm.nih.gov/25254246","citation_count":14,"is_preprint":false},{"pmid":"17951635","id":"PMC_17951635","title":"Saturation of the secretory pathway by overexpression of a hookworm (Necator americanus) Protein (Na-ASP1).","date":"2007","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/17951635","citation_count":14,"is_preprint":false},{"pmid":"16757812","id":"PMC_16757812","title":"Characterization of the human beta-secretase 2 (BACE2) 5'-flanking region: identification of a 268-bp region as the basal BACE2 promoter.","date":"2006","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/16757812","citation_count":14,"is_preprint":false},{"pmid":"38888964","id":"PMC_38888964","title":"The Alzheimer's disease-linked protease BACE2 cleaves VEGFR3 and modulates its signaling.","date":"2024","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38888964","citation_count":13,"is_preprint":false},{"pmid":"38139415","id":"PMC_38139415","title":"Next Generation Therapeutic Strategy for Treatment and Prevention of Alzheimer's Disease and Aging-Associated Cognitive Decline: Transient, Once-in-a-Lifetime-Only Depletion of Intraneuronal Aβ (iAβ) by Its Targeted Degradation via Augmentation of Intra-iAβ-Cleaving Activities of BACE1 and/or BACE2.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38139415","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49424,"output_tokens":7904,"usd":0.133416,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17430,"output_tokens":5037,"usd":0.106537,"stage2_stop_reason":"end_turn"},"total_usd":0.239953,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"BACE2 cleaves APP at the beta-secretase site (Asp1) and more efficiently at a site within the Aβ domain (near Phe19-Phe20); the Flemish missense mutation of APP markedly increases Aβ production by BACE2 but not BACE1; mutation of a conserved active-site Asp inhibits beta-site cleavage but not cleavage within Aβ by both enzymes.\",\n      \"method\": \"Cell-based cleavage assays, active-site mutagenesis, APP mutant analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro/cell-based cleavage assays combined with active-site mutagenesis in a focused study\",\n      \"pmids\": [\"10931940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"BACE2 is a membrane-anchored aspartic protease with a predicted transmembrane region; in vitro translation and cell transfection showed it encodes a glycosylated protein that localizes mainly intracellularly but also to some extent at the plasma membrane.\",\n      \"method\": \"In vitro translation, cell transfection, glycosylation analysis\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — cell transfection and in vitro translation, single lab, two methods\",\n      \"pmids\": [\"10683441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ASP1 (BACE2) expressed as an Fc fusion protein exhibits beta-secretase activity, cleaving both wild-type and Swedish-variant APP peptides at the beta-secretase site; overexpression of ASP1 in APP-expressing cells increases beta-secretase-derived soluble APP and the corresponding C-terminal fragment, but paradoxically decreases soluble Aβ secretion; ASP1 co-localizes with APP in Golgi/ER compartments.\",\n      \"method\": \"Cell-based overexpression, N-terminal sequencing of fusion protein, immunocytochemistry\",\n      \"journal\": \"Molecular and cellular neurosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based functional assay with protein-level readout and colocalization, single lab\",\n      \"pmids\": [\"11083922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"BACE2 prodomain processing is autocatalytic: cleavage occurs between Leu62 and Ala63; BACE2 cleaved a maltose-binding protein–prodomain fusion and a synthetic peptide at this site; mutation of the catalytic Asp (D110N) abolished processing; prodomain removal occurs intramolecularly within the ER/early Golgi, and mature BACE2 is expressed on the cell surface.\",\n      \"method\": \"Mutagenesis (D110N active-site mutant), fusion protein cleavage assay, synthetic peptide cleavage, cell fractionation/surface expression analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — active-site mutagenesis combined with in vitro peptide cleavage assay and cell biological localization, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"11316808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"In cells, BACE2 functions primarily as an alternative alpha-secretase, cleaving APP near the alpha-secretase site (mainly Phe19-Phe20 and Phe20-Ala21) with limited effect at the beta-site; purified BACE2 can be autoactivated in vitro; BACE2 localizes to ER, Golgi, TGN, endosomes, and plasma membrane, with localization dependent on its transmembrane domain; BACE2 chimeras that increase TGN localization do not alter APP processing patterns.\",\n      \"method\": \"Purified protein autoactivation, cell-based APP processing assay, subcellular localization by immunofluorescence, chimeric protein analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — purified protein in vitro assay, cell-based processing, and localization studies with chimeras, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"11423558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"BACE2 cleaves APP in cells between Phe19 and Phe20 within the Aβ domain (not at the beta-secretase site), resulting in increased APPsα and p3-like products and reduced Aβ production; this cleavage occurs in the Golgi and later secretory compartments; radiosequencing of the membrane-bound C-terminal cleavage product confirmed the exact cleavage site.\",\n      \"method\": \"Radiosequencing of C-terminal cleavage products, cell-based APP processing, compartment-specific analysis\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — radiosequencing (direct biochemical identification of cleavage site) combined with cell-based processing analysis, single lab\",\n      \"pmids\": [\"12065613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Stably transfected HEK293 cells overexpressing BACE2 produce the C-terminal fragment C79 (corresponding to cleavage between Phe19-Phe20), less genuine Aβ1-40/42, and higher sAPPβ and N-terminal-truncated Aβ species; BACE2 activity is enhanced by the Swedish APP mutation and is maximal at pH 4.5.\",\n      \"method\": \"Stable cell transfection, characterization of APP-derived catabolites, fluorimetric assay at varying pH\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stable cell lines with biochemical characterization of products, pH-activity profiling, single lab\",\n      \"pmids\": [\"12736275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Crystal structure of mature BACE2 in complex with a hydroxyethylamine transition-state inhibitor determined at 3.1 Å; structure confirms BACE2 follows the general fold of A1 aspartic proteases but its C-terminal domain is larger than other family members; differences in S3, S2, S1' and S2' active-site substrate pockets compared to BACE1 were identified; mature BACE2 was produced by autocatalytic activation of pro-BACE2 refolded from E. coli inclusion bodies.\",\n      \"method\": \"X-ray crystallography, recombinant protein expression and refolding, autocatalytic activation\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure determination with functional validation (autocatalytic activation), provides structural basis for active-site differences\",\n      \"pmids\": [\"16305800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BACE2 cleaves APP at a novel theta (θ) site downstream of the alpha-site, abolishing Aβ production; lentiviral overexpression of BACE2 markedly reduces Aβ production in primary neurons from Swedish-mutant APP transgenic mice; BACE1, not BACE2, is responsible for the major beta-secretase activity in Down syndrome.\",\n      \"method\": \"Lentiviral overexpression, primary neuronal culture, Aβ ELISA, APP cleavage site mapping\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — lentiviral overexpression with Aβ quantification in primary neurons, single lab\",\n      \"pmids\": [\"16816112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"BACE2 overexpression significantly increases sAPP levels (non-amyloidogenic) in conditioned media and markedly reduces Aβ production; knockdown of BACE2 results in increased APP C83; BACE2 processes APP within the Aβ domain at a site downstream of the alpha-secretase cleavage site, not at the beta-site; BACE2 and BACE1 have distinct transcriptional regulation (TATA-less promoter, Sp1 can regulate both but promoters share little similarity).\",\n      \"method\": \"Overexpression/knockdown in cells, sAPP and Aβ quantification, promoter characterization, transcription factor analysis\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based gain- and loss-of-function with biochemical readouts, single lab\",\n      \"pmids\": [\"15857888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Bace2 is the sheddase of the proproliferative plasma membrane protein Tmem27 in pancreatic β-cells; identified through siRNA screen; mice with functionally inactive Bace2 and insulin-resistant mice treated with a BACE2 inhibitor both display augmented β-cell mass and improved glucose homeostasis due to increased insulin levels.\",\n      \"method\": \"siRNA screen, genetic knockout mice, pharmacological inhibition, glucose homeostasis measurements, β-cell mass quantification\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — siRNA screen identification plus genetic KO mice and pharmacological inhibition with defined physiological readouts, replicated across multiple experimental systems\",\n      \"pmids\": [\"21907142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Tmem27 dimerization (mediated by intracellular cysteine) prevents Bace2 cleavage; extracellular asparagine glycosylation is essential for Tmem27 trafficking to the plasma membrane and its processing by Bace2; the amount of Tmem27 at the plasma membrane is proportional to total cell levels upon glucose stimulation and Bace2 inhibition; the double phenylalanine motif in the Tmem27 cleavage site acts as an intramolecular Bace2 inhibitor.\",\n      \"method\": \"Tmem27 mutational analysis, co-immunoprecipitation, glycosylation mutants, pharmacological inhibition, cell surface biotinylation\",\n      \"journal\": \"Biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutational analysis combined with multiple biochemical approaches defining substrate structural requirements for cleavage, single lab\",\n      \"pmids\": [\"22628310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BACE2 is a potent Aβ-degrading protease in vitro, cleaving Aβ at three peptide bonds (Phe19-Phe20, Phe20-Ala21, and Leu34-Met35, with Leu34-Met35 being the initial and principal site); BACE2 catalytic efficiency exceeds all known Aβ-degrading proteases except IDE; BACE2 overexpression in cultured cells lowers net Aβ levels comparably to IDE and greater than neprilysin or ECE1.\",\n      \"method\": \"Genome-scale cDNA screen, in vitro Aβ degradation assay, catalytic efficiency measurement, cell-based Aβ lowering assay\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assay with cleavage site mapping and catalytic efficiency measurement, plus cell-based validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"22986058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BACE2 processes PMEL (melanocyte protein) by cleaving its integral membrane form within the juxtamembrane domain, releasing the PMEL luminal domain into endosomal precursors for amyloid fibril formation and melanosome morphogenesis; Bace2-/- but not Bace1-/- mice display coat color defects; confirmed using RNA silencing, pharmacologic inhibition, and BACE2 overexpression in human melanocytic cell lines.\",\n      \"method\": \"Bace2 knockout mice, RNA silencing, pharmacological inhibition, BACE2 overexpression, biochemical and morphological analyses of melanocytes\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic KO mouse, RNA silencing, pharmacological inhibition, and overexpression all converging on same substrate and phenotype; multiple orthogonal methods\",\n      \"pmids\": [\"23754390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Systematic proteomic analysis of BACE2 substrates in pancreatic β-cells identified SEZ6L and SEZ6L2 (seizure 6 protein family members) as specific BACE2 substrates; BACE2 regulates a distinct, β-cell-enriched set of ectodomain shedding targets, non-redundant with BACE1 substrates.\",\n      \"method\": \"Quantitative proteomics (loss- and gain-of-function in vitro and in vivo models), mass spectrometry-based sheddome/secretome analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — systematic quantitative proteomics with both in vitro and in vivo loss/gain-of-function, multiple substrates identified\",\n      \"pmids\": [\"23430253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BACE2 degradation is mediated by the macroautophagy-lysosome pathway (half-life ~20 h); lysosomal inhibition increased BACE2 protein levels while proteasomal inhibition had no effect; lysosomal inhibition also increased BACE2 cleavage of APP.\",\n      \"method\": \"Pharmacological inhibition of lysosomes and proteasomes, protein half-life measurement, APP processing assay\",\n      \"journal\": \"The European journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection of degradation pathway with functional consequence on APP cleavage, single lab\",\n      \"pmids\": [\"23773066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Pharmacological inhibition of BACE2 (and BACE1) in mice inhibits PMEL17 proteolytic processing, leading to dose-dependent irreversible hair depigmentation; BACE2-mediated PMEL17 processing was confirmed in vitro in mouse and human melanocytes; bace2-/- mice show PMEL17 processing deficiency and hair depigmentation.\",\n      \"method\": \"Pharmacological inhibition (dual BACE1/2 inhibitor NB-360) in wild-type and bace2+/- and bace2-/- mice, in vitro melanocyte assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacological inhibition replicated across multiple genotypes in vivo plus in vitro validation in human and mouse melanocytes\",\n      \"pmids\": [\"26912421\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BACE2 cleaves human IAPP (islet amyloid polypeptide) at two distinct sites in the mature IAPP sequence; BACE2-mediated proteolysis modulates human IAPP fibrillation and leads to IAPP protein degradation.\",\n      \"method\": \"In vitro BACE2 cleavage assay with IAPP substrate, fibrillation assay, proteolysis mapping\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro cleavage assay with substrate site mapping, single lab, single method class\",\n      \"pmids\": [\"26840340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BACE2 is expressed in discrete subsets of neurons and glia in the adult mouse brain; four new BACE2 substrates in cultured glia were identified: VCAM-1, DNER, FGFR1, and plexin domain containing 2; TNF induced a drastic increase in BACE2-mediated shedding of VCAM-1 in CSF under proinflammatory conditions.\",\n      \"method\": \"Immunohistochemistry of mouse brain, proteomics of conditioned media from BACE2 KO vs WT glia, TNF stimulation, CSF analysis\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomic substrate identification with KO controls, TNF stimulation experiment, single lab\",\n      \"pmids\": [\"30456346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BACE2 cleaves the potassium channel Kv2.1 at Thr376, Ala717, and Ser769, disrupting Kv2.1 clustering on the cell membrane, resulting in decreased delayed rectifier K+ current and a hyperpolarizing shift; cleaved Kv2.1 forms reduce the delayed rectifier surge and reduce neuronal apoptosis.\",\n      \"method\": \"Cell-based cleavage assays, electrophysiology, site-directed identification of cleavage sites, apoptosis assays in primary neurons\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based cleavage site mapping combined with electrophysiology and apoptosis assays, single lab\",\n      \"pmids\": [\"29703946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In zebrafish, Bace2 cleaves the insulin receptor as a sheddase in melanophores; loss of bace2 (wanderlust mutant) causes hyperdendritic, hyperproliferative melanophores with aberrant localization due to hyperactive insulin/PI3K/mTOR signaling; inhibition of insulin/PI3Kγ/mTOR signaling rescues the wanderlust phenotype.\",\n      \"method\": \"Zebrafish bace2 mutant (wanderlust), chemical suppressor screen, insulin receptor cleavage assay, epistasis analysis with PI3K/mTOR inhibitors\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic mutant with defined substrate (insulin receptor), chemical suppressor screen establishing pathway epistasis, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"29804876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BACE2 also processes APP at the beta-site; the juxtamembrane helix (JH) of APP normally inhibits BACE2 beta-secretase activity; JH-disrupting mutations and clusterin binding to JH trigger BACE2-mediated beta-cleavage of APP; both BACE2 and clusterin are elevated in aged mouse brains, enhancing beta-cleavage during aging.\",\n      \"method\": \"Cell-based APP cleavage assays with JH mutants, clusterin binding/co-IP, aged mouse brain biochemistry\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis of APP JH combined with co-IP of clusterin and in vivo aging data, single lab\",\n      \"pmids\": [\"30626751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In pancreatic β-cells, BACE2 co-localizes with clathrin-coated vesicles at the plasma membrane; pharmacological inhibition or silencing of BACE2 increases BACE2 content in clathrin-coated vesicles, reduces insulin internalization rate, decreases insulin receptor β-subunit at the plasma membrane (increased in Golgi), and reduces insulin gene expression, indicating a role for BACE2 in insulin receptor trafficking.\",\n      \"method\": \"Immunofluorescence colocalization, pharmacological inhibition, siRNA silencing, insulin internalization assay, western blot of subcellular fractions\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic inhibition with subcellular localization and functional readouts, single lab\",\n      \"pmids\": [\"20943756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BACE2 trisomy in Down syndrome is a gene dose-sensitive AD suppressor; CRISPR/Cas9 elimination of the third copy of BACE2 in trisomy 21 cerebral organoids triggered AD-like pathology (Aβ deposits, tau pathology, neuronal loss); T21 organoids secrete increased Aβ-preventing (Aβ1-19) and Aβ-degradation products (Aβ1-20, Aβ1-34); this protective mechanism is cross-inhibited by BACE1 inhibitors.\",\n      \"method\": \"CRISPR/Cas9 gene editing of trisomy 21 cerebral organoids, Aβ peptide profiling by mass spectrometry, CSF analysis in DS patients, BACE1 inhibitor treatment\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — CRISPR gene editing in human organoid model with direct Aβ peptide profiling and CSF validation in human DS patients, multiple orthogonal approaches\",\n      \"pmids\": [\"32647257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BACE2 is the protease responsible for shedding of the lymphangiogenic receptor VEGFR3 from lymphatic endothelial cells; BACE2 (not BACE1) inactivation inhibited VEGFR3 shedding from primary human lymphatic endothelial cells, reduced soluble VEGFR3 in blood of mice, non-human primates, and humans, and increased full-length VEGFR3 and VEGFR3 signaling; in zebrafish, BACE2 inactivation enhanced LEC migration; soluble VEGFR3 can serve as pharmacodynamic plasma marker for BACE2 activity.\",\n      \"method\": \"Genetic and pharmacological BACE2 inactivation in primary human LECs, mouse/NHP/human plasma sVEGFR3 measurement, zebrafish LEC migration assay, VEGFR3 signaling analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic and pharmacological inhibition in multiple species (mouse, NHP, human, zebrafish) with biochemical and functional readouts, independently validated in vivo and in vitro\",\n      \"pmids\": [\"38888964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Multiple high-resolution crystal structures of BACE2 in six different packing environments were obtained using surface mutagenesis and co-crystallization with Fab fragments, Fynomers, and Xaperones; these structures define an ensemble of low-energy conformations accessible to the enzyme.\",\n      \"method\": \"X-ray crystallography with multiple crystallization helpers (Fab, Fynomers, Xaperones, surface mutagenesis)\",\n      \"journal\": \"Acta crystallographica. Section D, Biological crystallography\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple independent crystal structures in six packing environments, rigorous structural study\",\n      \"pmids\": [\"23695257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In rat astrocytes, beta-secretase activity and Aβ production are due to BACE2 (not BACE1), whose expression is blocked at the translational level in astrocytes; neuroinflammatory changes can both positively and negatively modulate BACE2-dependent beta-secretase activity in astrocytes.\",\n      \"method\": \"Primary astrocyte cultures, translational regulation analysis, Aβ production assay, proinflammatory stimulation\",\n      \"journal\": \"The European journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — primary cell culture with mechanistic dissection of translational block and functional Aβ production, single lab\",\n      \"pmids\": [\"21073551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BACE2 overexpression in ocular melanoma cells inhibits tumor progression in vitro and in vivo; BACE2 regulates TMEM38B expression, and the BACE2/TMEM38B axis modulates calcium release from the endoplasmic reticulum; increased N6-methyladenosine (m6A) RNA methylation leads to upregulation of BACE2 mRNA in ocular melanoma.\",\n      \"method\": \"BACE2 knockdown/overexpression in cell lines and xenografts, TMEM38B expression analysis, calcium flux assay, m6A methylation analysis\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss/gain-of-function in vitro and in vivo with pathway substrate (TMEM38B/calcium) identified, single lab\",\n      \"pmids\": [\"33601055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BACE2 loss-of-function mutation (BACE2G446R) in human pluripotent stem cell-derived brain organoids causes increased apoptosis and elevated Aβ oligomers resembling AD phenotypes; these phenotypes are rescued by APP removal; BACE2WT overexpression in organoids carrying APP Swedish/Indiana mutations attenuates Aβ accumulation and neuronal cell death.\",\n      \"method\": \"hPSC-derived brain organoids with BACE2 loss-of-function variant, CRISPR/APP knockout rescue, BACE2 overexpression in AD mutant organoids\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human organoid model with loss-of-function and gain-of-function rescue experiments, single lab\",\n      \"pmids\": [\"35110536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"BACE2 knockout mice display an overall healthy phenotype; combined BACE1/BACE2 deficiency enhances BACE1-/- lethality; BACE2 contributes to Aβ generation in glia (which lack BACE1 activity), not in neurons.\",\n      \"method\": \"Genetic knockout mice (single and double KO), biochemical Aβ analysis in neurons and glia\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO mouse models (single and double) with biochemical Aβ analysis and cell-type-specific dissection, replicated in vivo\",\n      \"pmids\": [\"15987683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In zebrafish, loss of Bace2 results in a specific melanocyte migration and morphology phenotype not observed in Bace1-/- fish; double homozygous bace1-/-; bace2-/- fish do not enhance single mutant phenotypes, indicating non-redundant, distinct physiological functions for Bace1 and Bace2.\",\n      \"method\": \"Zinc finger nuclease-mediated gene editing to generate Bace1 and Bace2 KO zebrafish, phenotypic analysis of single and double mutants\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and double-KO zebrafish with defined non-redundant phenotypes, single lab\",\n      \"pmids\": [\"23406323\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BACE2 is a membrane-anchored aspartyl protease that undergoes autocatalytic prodomain removal in the ER/Golgi and traffics through TGN, endosomes, and plasma membrane; it cleaves multiple substrates including APP (primarily at the Phe19-Phe20 theta-site to suppress Aβ production, but also conditionally at the beta-site), PMEL17 (releasing the luminal domain for functional amyloid fibril formation in melanosomes), Tmem27 (regulating pancreatic β-cell mass and glucose homeostasis), IAPP, Kv2.1 (reducing neuronal apoptosis), the insulin receptor (negatively regulating insulin/PI3K/mTOR signaling in melanophores), VEGFR3 (modulating lymphangiogenic signaling), and additional glial substrates (VCAM-1, DNER, FGFR1, SEZ6L/SEZ6L2) that become prominent under proinflammatory TNF stimulation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BACE2 is a membrane-anchored aspartyl protease of the A1 family that functions as a regulated ectodomain sheddase, processing a diverse set of transmembrane substrates across the secretory and endosomal pathways [#7, #1]. It matures by autocatalytic removal of its prodomain (cleavage between Leu62 and Ala63) within the ER/early Golgi, a step abolished by mutation of the catalytic aspartate (D110N), after which mature enzyme traffics through ER, Golgi, TGN, endosomes, and the plasma membrane in a transmembrane-domain-dependent manner [#3, #4]. Its crystal structure confirms the canonical aspartic-protease fold with an enlarged C-terminal domain and active-site pockets (S3, S2, S1', S2') distinct from BACE1, and the enzyme samples an ensemble of low-energy conformations [#7, #25]. On APP, BACE2 acts principally as an anti-amyloidogenic protease, cleaving within the Aβ domain at the theta site (Phe19-Phe20) to raise sAPP/p3-like products and suppress Aβ, while retaining conditional beta-site activity that is normally restrained by the APP juxtamembrane helix and unmasked by clusterin binding during aging [#5, #8, #21]; it additionally degrades Aβ peptide directly with catalytic efficiency rivaling IDE [#12]. This protective function is gene-dose sensitive: BACE2 trisomy suppresses Alzheimer-like pathology in Down syndrome organoids, and loss-of-function variants drive Aβ-dependent neuronal death [#23, #28]. Beyond the brain, BACE2 sheds Tmem27 to control pancreatic β-cell mass and glucose homeostasis, processes the melanosomal protein PMEL to enable functional amyloid fibril formation and pigmentation, cleaves the lymphangiogenic receptor VEGFR3 to limit its signaling, and acts on the insulin receptor, Kv2.1, IAPP, and glial substrates including SEZ6L/SEZ6L2 and VCAM-1 under inflammatory conditions [#10, #13, #24, #20, #19, #17, #14, #18]. Genetic ablation in mice and zebrafish yields viable animals with pigmentation and melanophore phenotypes non-redundant with BACE1 [#13, #29, #30].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Establishing that BACE2 is a membrane-anchored aspartic protease capable of cleaving APP defined the enzyme's basic biochemical identity and placed it alongside BACE1 as a candidate amyloidogenic protease.\",\n      \"evidence\": \"In vitro translation, cell transfection, glycosylation analysis, and cell-based cleavage/active-site mutagenesis assays on APP\",\n      \"pmids\": [\"10683441\", \"10931940\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve whether net effect on Aβ is amyloidogenic or anti-amyloidogenic\", \"Physiological substrates beyond APP unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defining the autocatalytic prodomain cleavage site and showing BACE2 acts mainly within the Aβ domain rather than at the beta-site reframed its role as an alternative alpha/theta-secretase and clarified its maturation and trafficking.\",\n      \"evidence\": \"D110N active-site mutagenesis, fusion-protein and synthetic-peptide cleavage assays, cell fractionation, and subcellular localization with TM-domain chimeras\",\n      \"pmids\": [\"11316808\", \"11423558\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Compartment in which physiologically relevant cleavage occurs not fully resolved\", \"Regulation of trafficking not defined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Direct radiosequencing pinned the APP cleavage to Phe19-Phe20 within the Aβ domain, biochemically proving BACE2 suppresses rather than generates Aβ.\",\n      \"evidence\": \"Radiosequencing of membrane-bound C-terminal cleavage products with compartment-specific cell-based processing\",\n      \"pmids\": [\"12065613\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this anti-amyloidogenic activity operates in vivo in human brain untested at this stage\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Crystallization of mature BACE2 with a transition-state inhibitor provided the structural basis for active-site differences from BACE1, enabling rational inhibitor and selectivity considerations.\",\n      \"evidence\": \"X-ray crystallography at 3.1 Å of autocatalytically activated, refolded recombinant BACE2\",\n      \"pmids\": [\"16305800\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No substrate-bound structure\", \"Conformational dynamics not captured by single structure\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Knockout mice and cell-type analysis showed BACE2 is dispensable for normal development but contributes to glial (not neuronal) Aβ generation, distinguishing it physiologically from BACE1.\",\n      \"evidence\": \"Single and double BACE1/BACE2 knockout mice with biochemical Aβ analysis in neurons and glia\",\n      \"pmids\": [\"15987683\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological substrate underlying any phenotype not identified here\", \"Cell-type basis of glial-specific activity unexplained\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identification of Tmem27 as a BACE2 substrate established a non-neural physiological role controlling pancreatic β-cell mass and glucose homeostasis, opening BACE2 as a metabolic drug target.\",\n      \"evidence\": \"siRNA screen, genetic knockout mice, pharmacological inhibition with β-cell mass and glucose readouts; substrate structural requirements defined by mutagenesis and biochemistry\",\n      \"pmids\": [\"21907142\", \"22628310\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking Tmem27 shedding to proliferation incomplete\", \"Translation of inhibitor metabolic effects to humans untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstration that BACE2 directly degrades Aβ peptide with IDE-like efficiency added a second anti-amyloidogenic mechanism beyond protective APP cleavage.\",\n      \"evidence\": \"Genome-scale cDNA screen, in vitro Aβ degradation with cleavage-site mapping and catalytic efficiency measurement, cell-based Aβ lowering\",\n      \"pmids\": [\"22986058\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo contribution of Aβ degradation versus APP cleavage not quantified\", \"Cellular site of Aβ degradation unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of PMEL processing and SEZ6L/SEZ6L2 shedding defined BACE2's physiological substrate repertoire in melanosomes and β-cells, explaining pigmentation phenotypes and tissue-specific, non-redundant function.\",\n      \"evidence\": \"Bace2 knockout mice, RNA silencing, pharmacologic inhibition, overexpression, and quantitative sheddome proteomics; additional crystal structures defining conformational ensemble\",\n      \"pmids\": [\"23754390\", \"23430253\", \"23695257\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full substrate spectrum across tissues not exhaustively mapped\", \"Signaling consequences of SEZ6L family shedding unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Non-redundant phenotypes in zebrafish and definition of BACE2 turnover via macroautophagy clarified its distinct biology and a route for regulating its abundance and activity.\",\n      \"evidence\": \"Zinc-finger-nuclease KO and double-KO zebrafish phenotyping; pharmacological lysosome/proteasome inhibition with half-life and APP-cleavage readouts\",\n      \"pmids\": [\"23406323\", \"23773066\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals targeting BACE2 to lysosomal degradation unknown\", \"Relationship of zebrafish melanocyte phenotype to mammalian substrates partial\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Pharmacological inhibition causing irreversible hair depigmentation linked on-target BACE2 PMEL processing to a defined safety/biomarker consequence of BACE inhibitors.\",\n      \"evidence\": \"Dual BACE1/2 inhibitor across wild-type and bace2 genotypes in vivo plus in vitro melanocyte validation; in vitro IAPP cleavage/fibrillation mapping\",\n      \"pmids\": [\"26912421\", \"26840340\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"IAPP cleavage shown only in vitro, physiological relevance unestablished\", \"Reversibility/mechanism of pigmentation loss incomplete\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Discovery of insulin receptor, Kv2.1, and glial inflammatory substrates broadened BACE2's signaling reach into PI3K/mTOR control, neuronal excitability/apoptosis, and neuroinflammation.\",\n      \"evidence\": \"Zebrafish bace2 mutant with chemical suppressor epistasis; cell-based Kv2.1 cleavage mapping with electrophysiology and apoptosis assays; glial sheddome proteomics with TNF stimulation\",\n      \"pmids\": [\"29804876\", \"29703946\", \"30456346\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mammalian relevance of zebrafish insulin-receptor shedding untested\", \"Physiological role of inflammation-induced VCAM-1 shedding undefined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showing that the APP juxtamembrane helix restrains BACE2 beta-cleavage and that clusterin/aging unmask it provided a conditional switch converting BACE2 from protective to amyloidogenic.\",\n      \"evidence\": \"Cell-based APP cleavage assays with JH mutants, clusterin co-IP, and aged mouse brain biochemistry\",\n      \"pmids\": [\"30626751\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative contribution of this switch to age-related amyloidogenesis unknown\", \"Structural basis of clusterin-JH interaction not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Gene-dose experiments in human trisomy 21 organoids established BACE2 as a dose-sensitive Alzheimer suppressor and revealed cross-inhibition of its protective activity by BACE1 inhibitors.\",\n      \"evidence\": \"CRISPR/Cas9 editing of trisomy 21 cerebral organoids, Aβ peptide profiling by mass spectrometry, DS CSF analysis, BACE1 inhibitor treatment; complementary LOF-variant organoid rescue by APP removal\",\n      \"pmids\": [\"32647257\", \"35110536\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BACE2 enhancement is therapeutically tractable untested\", \"In vivo human relevance beyond organoid/CSF data limited\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identifying VEGFR3 as a BACE2-specific shed substrate connected the enzyme to lymphangiogenic signaling and provided soluble VEGFR3 as a translational pharmacodynamic marker of BACE2 activity.\",\n      \"evidence\": \"Genetic and pharmacological BACE2 inactivation in human LECs, plasma sVEGFR3 measurement in mouse/NHP/human, zebrafish LEC migration, VEGFR3 signaling analysis\",\n      \"pmids\": [\"38888964\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological/pathological consequences of altered lymphangiogenesis upon chronic inhibition unclear\", \"Tissue specificity of VEGFR3 shedding not mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BACE2 substrate selection and the protective-versus-amyloidogenic balance are coordinated across tissues, trafficking compartments, and disease states remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of how compartmental localization dictates which substrate is cleaved\", \"Regulators that toggle theta- versus beta-site APP cleavage in vivo unknown\", \"Therapeutic window separating protective Aβ effects from pigmentation/metabolic/lymphatic on-target liabilities undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 5, 10, 13, 19, 24]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [3, 7, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 3, 4, 22]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [2, 4, 5]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [3, 4]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 5]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 10, 13, 24]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [23, 28]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"APP\", \"TMEM27\", \"PMEL\", \"VEGFR3\", \"KCNB1\", \"INSR\", \"SEZ6L\", \"VCAM1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":7,"faith_total":7,"faith_pct":100.0}}